Withdrawal of non-binding proposal

26^th Aug 2015

In the Company’s announcement of the conclusion of its strategic review released on 18 August, 2015, reference was made to a non-binding preliminary proposal of US$110 million for the Company’s Point-of-Care business. That proposal has now been withdrawn.

The proposals referenced in the Company’s announcements released on 24 August, 2015 are not affected.

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF to highlight Lucica® Glycated Albumin-L assay for diabetes patient monitoring at AACC 2019

EKF announces the availability of a liquid, enzymatic test for glycated albumin (GA) that was recently FDA cleared for sales in the U.S. GA, used for intermediate term monitoring of glycemic control in diabetes patients, will be showcased at the 2019 AACC.

EKF at InterLab - Algiers, Algeria 2019

The third edition of the exhibition will be held on 25-27 September 2019 at the Palais des Expositions, SAFEX, Algiers, Algeria.

EKF Quo-Test supports improved medical management of diabetic retinopathy patients

Quo-Test^® HbA1c analyzer is successfully supporting improved medical management of patients with sight-threatening diabetic retinopathy (STDR).

SensLab is sponsoring the 36th Leipzig Triathlon

SensLab, an EKF Diagnostics company, will be testing triathletes lactate levels at the 36^th Leipzig Triathlon to be held at Kulkwitzer on the 28^th July 2019.

Bugs Runny: New study identifies bugs that help runners

A recent article in Nature Medicine by Scheiman et al has identified a strain of gut microbes present in marathon runners that improves run times. The scientists at Harvard and the Joslin Institute took poop samples from 15 runners at the 2015 Boston marathon.